Preliminary data showed that the combination of sitravatinib and tislelizumab is well tolerated and may promote antitumor activity when administered to patients with platinum-resistant ovarian cancer, according to a press release from BieGene, Ltd, which reported data from a phase Ib study at the 2019 European Society of Oncology Immuno-Oncology Congress in Geneva, Switzerland.
Hope S. Rugo, MD, FASCO, discusses how the phase 3 ELEVATE study evaluates the combination of elacestrant with abemaciclib in patients with ER+/HER2– advanced or…
Joe Leach, MD, discusses how comprehensive biomarker testing has impacted treatment selection for patients with small cell lung cancer.
In a discussion with Peers & Perspectives in Oncology, fellowship program director Marc J. Braunstein, MD, PhD, FACP, and hematology/oncology fellow Olivia Main, MD, talk…
Following a recent update in to NCCN gGuidelines, Drs. Garcia- Manero and Swoboda introduce themselves and theirwill discussion about the changing landscape of lower-risk myelodysplastic…
With the Oncology Brothers, Uma Borate, MD, discusses how ziftomenib is showing promising results as a targeted therapy for NPM1-mutated and KMT2A-rearranged acute myeloid leukemia…
During a Case-Based Roundtable® event, Daniel A. Ermann, MD, discussed evaluation and treatment for a patient with relapsed chronic lymphocytic leukemia after receiving venetoclax and obinutuzumab.
Anita D’Souza, MD, discusses an abstract looking at the combination of teclistamab-cqyv, daratumumab, and pomalidomide in 2 phase studies for patients with multiple myeloma.
During a Case-Based Roundtable® event, Omar Nadeem, MD, and participants discussed managing toxicities of talquetamab in the second article of a 2-part series.
R289, a dual IRAK1/4 inhibitor, has received fast track status from the FDA for treating transfusion-dependent lower-risk MDS in patients with inadequate responses to prior…
Frontline tyrosine kinase inhibitors are well-established for chronic myelogenous leukemia, but some patients experience inadequate response or adverse events, highlighting the need for novel therapies.
